View Article

Abstract

Creating a coenzyme Q10 (CoQ10) microemulsion system with enhanced solubility, penetration, and wound healing effectiveness was the aim of this study. The material was chosen and verified to be nanosized (less than 20 nm) and thermodynamically stable using the pseudo-ternary diagram in accordance with the results of tests for thermodynamic stability and dilution. Compared to microemulsions with a surfactant/co-surfactant Greater penetration efficacy was achieved by the CoQ10-loaded microemulsion at a (S/Cos) ratio of 3:1 or 4:1 (w/w%). Additionally, fibroblasts and keratinocytes demonstrated a rather rapid wound-healing response to the CoQ10-loaded microemulsion made of isopropyl myristate (IPM), Cremophor EL, and Transcutol HP at a 2:1 S/Cos ratio." A microemulsion based on IPM, Cremophor EL, and Transcutol HP may be a useful tool for topical CoQ10 distribution and for giving other drugs that have problems with oral absorption, according to these studies.

Keywords

skin, solubility, wound healing effectiveness, microemulsion, and coenzyme Q10...

Introduction

The body's outermost layer, the body's initial defence against ambient physical, chemical, and biological factors is the skin, including moisture, UV rays, and toxins and drugs. (Pathogen and allergen)  (1).  The nucleated epidermis provides additional essential elements such cell-cell junctions and cytoskeletal proteins, but the stratum corneum makes up the majority of the physical barrier (2).  Important to innate immunity is the chemical or biochemical barrier include macrophages, hydrolytic enzymes, lipids, acids, and antimicrobial peptides (3). Immune system components that are humoral and cellular make up the (adaptive) immunological barrier (4).  Water loss in the Stratum corneum  hydrates its outer layers, preserving flexibility and facilitating enzymatic reactions that drive its maturation(5). The stratum corneum layer at the outermost layer controls the flow of water and chemicals between the organism and its surroundings, determining the skin's barrier qualities(6). These include techniques like microdialysers, quantitative autoradiography, extraction, and skin layer stripping(7). Consequently, "a system of water, oil, and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution" is a microemulsion(8). In microemulsions, which are carriers that are thermodynamically stable, Water and oil are stabilized by amphiphiles like co-surfactants and surfactants. These systems pharmacological stability, ease of manufacturing, and scalability make them typically beneficial(9) The creation of dispersions occurs when the appropriate amounts of oil, water, and surfactant or cosurfactant are mixed.  The excipient selection is limited, and the medication The mode of administration needs to be biocompatible. Plant and vegetable oils, triglycerides, fatty acid esters, corn, cottonseed, orange, clove, peppermint, eucalyptol, and coconut (e.g., ethyl oleate, isopropyl myristate, or IPM) have all been utilized as oil components in the creation of biocompatible microemulsion.

 

 

 

 

Fig 1: Skin

 

 Interactions that result in increased penetration include the disruption or disintegration of SC lipids, contact with SC proteins, skin hydration, strengthening drug partitioning into the skin or improving drug solubility in the vehicle (8) . For example, a lower melting point and greater solubility for testosterone resulted from a combination of eutectic production between menthol and testosterone as well as between menthol and skin lipids. Additionally, it altered the properties of the skin's barrier, which enhanced the drug's delivery  Adenosine triphosphate and cellular energy are produced by Coenzyme Q10 (CoQ10), which is found inside the inner mitochondrial membrane. The poor solubility and dispersibility of CoQ10 in polar solvents like ethanol and water is one of the biggest obstacles to its use as a supplement. According to Terao et al. CoQ10 is less than 0.1 μg/m soluble in water. Intake of CoQ10 has been shown to reduce the signs and symptoms of early Parkinson's disease and Huntington's. formulations based on oil and oil-in-water (O/W) emulsions, which are aqueous solutions with a dispersed oil phase and encapsulate a variety of poorly soluble compounds, are typically made using equipment like an extruder and energy-supplying high-pressure homogenizer to expand the water/oil interfacial area.\ These conditions have been successfully treated by CoQ10, and several clinical studies are looking at its potential as a medication or dietary supplement(8). Because of their special properties, which include their ability to increase Lipids are now very sought-after options for oral formulation carriers because of their ability to transform enterocyte-based drug transport and disposition, attract intestinal lymphatic drug transport, and make water-insoluble medications soluble in the intestinal environment. CoQ10 has drawn interest for its potential use as a treatment for a number of illnesses, such as cancer, diabetes, and cardiovascular disease The benefits of CoQ10 for the skin have been clearly shown in recent research, and they are associated with improved fibroblast proliferation, shielding cells from oxidative damage and producing basement membrane constituents,  such as collagen Fibers, keratinocytes, and lamina (9). In order to increase the likelihood of skin irritation, they must be effective as skin penetration enhancers they must be used in high concentrations. As a result, using cyclodextrin as a chemical penetration enhancer results in inadequate transdermal distribution of potential medication molecules Because of its biophysical qualities (hydrating power) and good sensory qualities (fast penetration, merging textures), nano emulsion is easily used in skin care. The significant potential for drug solubility(9) in the NE system may raise the skin's thermodynamic activity The NE internal phase's readily adjusted drug affinity, which separates into the stratum cornea, increases the pace at which the medicament penetrates the cornea This review's objective is to present the state of the art on microemulsions' ability to solubilize oral medications and nutraceuticals, which are naturally occurring substances that have health advantages. This review does not include theories of drug release,  bioavailability, or microemulsions Numerous Additional potential medications Studies have been conducted on the use of microemulsions in cell-targeting or peptide formulations for intramuscular delivery. and pulmonary intra-vaginal or intrarectal administration delivery systems for lipophilic drugs such microslides, steroids, and hormones .The stratum corneal lipid lamellae are Oleic acid breaks down a mixture of water and ethanol,  as demonstrated by this study. However, this investigation demonstrated that iontophoresis did not enhance AVP penetration via linoleic prepared skin. Drug permeation across the skin can be promoted by chemicals belonging to many different chemical groups, such as: alcohols, polyols, long-chain fatty alcohols, acids, esters and alkyl methyl sulfoxides, terpenes, a zones, surfactants, and others(9-10).  Since the subsequent layer is hydrophilic, a hydrophobic material can enter the SC with ease but stays stored there. The skin's barrier qualities are determined by the outermost stratum corneum layer, which also controls the flow of water and chemicals between the body and its surroundings. When water, oil, and surfactant/cosurfactant are combined in the right amounts, the dispersions are created (9). Because surfactants and cosurfactants are present, the interfacial layer protects the encapsulated medications in the microdomains from enzymatic destruction while also facilitating membrane permeability (9). various triglycerides and fatty acid esters, including isopropyl myristate (IPM) and ethyl oleate, have been used as oil components in the production of biocompatible microemulsions. For instance, prior research has shown that consuming CoQ10 slows the development of ventricular dysfunction, arrhythmias, angina pectoris, and chronic heart failure.  Small compounds that preferentially travel across the intercellular pathway are known as penetrants. Diffusion rates are determined by physicochemical properties including solubility, hydrogen bonding ability, and molecular weight or volume, as well as lipophilicity. When it comes to skin conditions, transdermal drug delivery is more practical than oral drug delivery since direct application permits more buildup of the medicine at the target with fewer negative consequences (such systemic toxicity). Furthermore, according to previous investigations, Anti-inflammatory and wound-healing properties were demonstrated by CoQ10. Consequently, improving reaching the deep layers of the epidermis by penetration into (10)the stratum corneum without producing significant absorption into the blood circulation is the true difficulty of antioxidants . Measurements of viscosity and conductivity, as well as more sophisticated techniques NMR dynamic light scattering (DLS), cryo-TEM, pulsed gradient spin echo (self-diffusion), small angle X-ray scattering (SAXS), small angle neutron scattering (SANS), and, are some of the key techniques pertinent to the characterization of the microemulsions  (9)

Advantages:

  1. Enhanced Skin Penetration

Due to their extremely small droplet sizes (20–200 nm), microemulsions have a larger surface area and better allow lipophilic CoQ10 to access layers of viable skin by penetrating the stratum corneum (10).

 

 

 

Fig 2: Skin penetration.

 

  1. Improved Solubility & Stability

Despite being poorly soluble in water, CoQ10 dissolves well in microemulsions' oil phase. This system guards against oxidation and photodegradation of CoQ10 by utilizing antioxidants, such as vitamin E (11).

  1. Sustained/Controlled Release

By serving as reservoirs, microemulsions can release CoQ10 gradually over a longer period of time, enhancing its antioxidant effects on the skin (12).

 

 

 

 

Fig 3: Controlled Released

 

  1. Skin Hydration & Barrier Support

Glycerine, hyaluronic acid, and panthenol are examples of hydrophilic ingredients in the microemulsion that improve hydration, strengthen the skin barrier, and work in concert with CoQ10's restorative properties (13).

 

 

 

 

 

Fig 4 Skin Hydration

 

5. Thermodynamic Stability

 Because microemulsions are thermodynamically stable, they are less likely to undergo   phase separation while being stored than ordinary emulsion (14).

  1. Cosmetic Elegance

 They typically have lovely skin, are transparent, and aren't oily, all of which are crucial for  customer acceptability (15).

  1. Customization.

For multipurpose skin-regeneration products, formulation flexibility enables the addition of co-actives (panthenol, vitamin E) and penetration enhancers (16).

Disadvantage:

1.Potential Irritation from Surfactants

If microemulsions are not carefully chosen, their comparatively high surfactant/co-surfactant concentrations could irritate delicate skin or damage the barrier (17).

2. Limited Drug Loading

Even though CoQ10 is lipophilic, the amount that can be added without making the microemulsion unstable is still limited (18).

 

 

 

Fig 5: Limited drug loading

 

3. Stability Concerns Under Stress

Even though they are thermodynamically stable, microemulsions can become unstable when exposed to extreme temperature changes or dilution, such as when combined with other cosmetics (19).

4. Packaging Challenges To stop CoQ10 deterioration, they need non-reactive, oxygen-and light-protected packaging; the price may be greater (20)

5. Regulatory & Safety Testing

For regulatory approval, more irritation/safety studies might be necessary due to their unique nature and penetration enhancer application (21).

6.Formulation Complexity Choosing the right surfactant/co-surfactant ratios and creating a strong pseudo-ternary phase diagram can take a lot of effort and resources (22)

7. Shorter Shelf-Life Without Proper Antioxidants

Choosing the right surfactant/co-surfactant ratios and creating a strong pseudo-ternary phase diagram can take a lot of effort and resources (23).

Materials :

CoQ10, oleic acid (OA), and isopropyl myristate (IPM) were provided by Japan's Tokyo Chemical Industry (TCI); Gatepost (Gatepost, France) supplied Labrafil M1944, Labra sol, and Transductal HP; Daesung Chemicals (Daesung, Korea) supplied cottonseed oil; the Duskin Corporation (Duskin, Korea) supplied Propylene glycol (PG) and polyethylene glycol (PEG) 400 by Tween 80, Sigma–Aldrich (St. Louis, MO, USA). supplied Cremophor EL (Calliphora); and ethyl (Dusan, Korea) and HPLC-quality isopropyl alcohol were present (24).

Quantitative Analysis of CoQ10 :

A mobile phase made of a 75:25 v/v % ethyl alcohol isopropanol mixture was used to dilute each supernatant. To separate the particles, 5 μm, or 4.6 × 150 nm, particles, in the C18 column, Young Jin Biochrome Aegis Pak, Sonograms, Korea) was utilized. In all studies, The Hitachi Lunchroom Elite The HPLC L-2000 series, a pump L-2130, a column oven L-2300, and an autosampler L-2200  were utilized. " The settings were column temperature, injection volume (20 μL), detection (275 nm), and flow rate (1 mL/min) (25).

Construction of Pseudo-Ternary Phase Diagram :

At room temperature, the chosen oil, water, and the surfactant and co-surfactant mixture were all displayed in pseudo-ternary phase diagrams using the titration method. HPLC (Hitachi Lach Rom Elite, Tokyo, Japan) is an experimental surfactant and co-surfactant range chromatography method that optimally maintains hydrophilic and lipophilic balance (HLB)  For creating the o/w microemulsion, the range is 10 to 13. Before using experimental testing methods, the surfactants Labra sol, Tween 80, and Cremophor EL were theoretically chosen.  The experimental investigation first chose a suitable surfactant. To put it succinctly, a pipette (PIPETMAN®, Gilson, France) This approach involved adding 3 mL of each surfactant solution (15 w/v%) to 5 μL of each type of oil.  while providing gentle magnetic stirring until the mixture became somewhat confused.  The amount of oil required for emulsification was noted During the titration procedure, each sample was shaken until it reached an equilibrium state. In order to assess the surfactants' capacity for emulsification The oil and surfactant mixes were homogenized and then diluted(25-26) with double-distilled water A UV spectrophotometer was used to measure the transmittance at 650 nm after the produced emulsions had been stored for one hour. Additionally, an acceptable co-surfactant was chosen within the range of the microemulsion zone created by the oil and surfactant..  Following the initial 1:1 ratio of the surfactant/co-surfactant (S/cos) combination, the following weight ratios of oil and S/Cos mixtures were developed:  were used to generate the pseudo-ternary diagrams:  1:8; 1:9. 1:6-7, 1:5, 1:4, 1:2, 1:1, 1:0.7, 1:0.43, and 1:0.11. We used the water titration approach to create the pseudo-ternary phase diagrams. The S/Co's mixture was chosen and stirred at room temperature after dropwise additions of double-distilled water to a specific volume of oil(26). When the solutions were hazy during titration, the microemulsion's and other phases' borders were noted and evaluated for turbidity and transparency (26).

A CoQ10-Loaded o/w Microemulsion is prepared by:

Using 5% to 15% oil, 30% to 60% S/Co’s mixture, and 40% to 60% double-distilled water,  different formulations were developed using phase diagrams based on the first experiment, incorporating CoQ10(27).  To put it briefly, CoQ10 was slowly dissolved into the oil and S/Coos mixture that had been previously weighed. After adding the specified amount of water, the mixture was sonicated to produce a clear liquid. The dilution test and the thermodynamic stability test were used to assess each formulation to enhance the o/w microemulsion loaded with CoQ10 (27).

Permeation Experiment

Membrane Permeation Experiment in Vitro:

There between the donor and receiver compartments of the Franz diffusion cell device was a semipermeable polycarbonate membrane (0.4 μm, Whatman 800282). Nucleopores TM, NJ, USA, GE Healthcare Bio-Sciences Corp.).  Next, at 37 °C, Under the membrane, the receptor compartment was filled with 9 mL of media without creating any bubbles (28). After making the CoQ10-loaded o/w microemulsion, the donor compartment was filled. The donor compartment was filled with two grams of each microemulsion. "The control was supplied with the same quantity of CoQ10 simultaneously dissolved in a solution of 1% sodium lauryl sulphate .  HPLC was used to track and quantitatively analysed the CoQ10 penetration as previously mentioned (28)

In Vitro Skin Permeation Experiment

A receptor compartment Additionally, the Franz diffusion cell equipment used to investigate skin penetration had an effective penetration area of 1.43 cm³.  Inje Institutional Animal Care and Use Committee of the University (IACUC) procedure (IACUC 2019-015) was approved on September 26, 2019, so We collected and used the recently removed skin from female hairless mice (SKH-1)(28-29) .In short, the adhering Phosphate-buffered saline (pH 7.4) was used to wash the mouse skin after the fat layer was removed. Following that, In the Franz diffusion cell apparatus system, the skin was positioned in between the donor and receptor compartments.  After that, The receptor space under the epidermis received 9 mL of medium without producing any bubbles(28) . After the system was ready, the donor compartment also received two grams of each chosen microemulsion.   Additionally, the control group received the same quantity of CoQ10, which was diluted with 1% sodium lauryl sulphate(27-28).  To get rid of the extra The skin was treated with CoQ10, removed the following day, Phosphate-buffered saline was used for washing. Each skin was cut apart and sonicated to release the CoQ10 (29)

Physicochemical analysis of the o/w microemulsion loaded with CoQ10: (30)

A dilution test and thermodynamic experiments were used to determine the best composition for three formulations (F2, F10, and F18). The CoQ10-loaded microemulsions' droplet size and zeta potential are displayed.  Additionally, measurements were made of the formulations' pH and CoQ10 medication concentration. Each microemulsion's size was less than 20 nm, according to the results, and there was no discernible variation. Because of the (30) low polydispersity index close to zero, all formulations displayed uniform droplet size, even if it was relatively low in comparison to F10 and F18.  Each formulation's zeta potential value, which varied from -11 to -15 mV, was rather negative . The approximately 100% showed that CoQ10 was well-entrapped in the oil phase made of IPM.  drug content of each formulation, irrespective of the S/Cos ratio While their S/Cos ratios and compositions have varied so far, F2, F10, and F18 as a group showed no appreciable variations in the microemulsion's physicochemical characteristics (31).

The impact that COQ10 has on skin regeneration:

Cell proliferation Before the skin regeneration project was initially evaluated in  the representative skin cell lines, NIH3T3 fibroblast cells and keratinocyte cells that are HaCaT. The representative skin cell lines are NIH3T3 fibroblast cells and the cells. Both cell lines' proliferation was enhanced in each set of trials, and F2 showed no cytotoxicity in comparison to the control. ."In order to demonstrate the improved impact the effects of CoQ10 on skin regeneration. The cell scratch test, also called the wound healing assay, was employed in vitro, was carried out following the results(30-32).  "In order to evaluate the process of wound healing and mending, the cell scratch test was used in our experiment on keratinocytes and fibroblasts. Following scratching, which was observed for 36 hours, the cells in both cell lines moved in the direction of the provisional gap. "Every fibroblast and keratinocyte picture was displayed in In comparison to the F2-treated group under control (the top line)) showed a comparatively a comparatively poor influence on wound healing and a slow migration pace. The F2-treated cohort  demonstrated a faster rate of wound healing in both cells as compared to the(The bottom line. Both cells showed that the F2-treated group was more effective than the control group at wound healing(32). For example, F2 had a 98.95% greater effect on wound closure in HaCaT cells than the control group. Under microscopic examination, After a 24-hour exposure, for example, F2 in HaCaT cells accelerated wound closure, producing a wound healing zone.  At the same time point after a 24-hour exposure under a microscope, Of the cells in the other group, 98.95% of the wound healing region was visible, compared to 55.44% in the control group.  Moreover, the control group's cells showed 55.44% of the area that is healing from the wound simultaneously(32-33)

Protransfersome (Protransf-CoQ10) loaded with CoQ10 is prepared

With Tween 80, oleic acid, and L-α-phosphatidylcholine  made up the protransfersome, which was synthesized using a modified version of the Gupta method.  (2012). CoQ10 was initially stirred in an oleic acid and Tween 80 solution until completely dissolved.  Lastly, to create Protransf-CoQ10, The Stirring was done until the L-α-phosphatidylcholine was dissolved (34)

Emulgel preparation with a protransfersome loaded with CoQ10

To make a CoQ10-loaded protransfersome emulgel,The emulgel foundation was supplemented with Protransf-CoQ10 at a final concentration of 1% CoQ10.  To create a homogenous emulgel basis, Span 80 and Tween 80 were combined 1:1 with Carbopol 940)(35). and then Triethylamine (TEA) was added to bring the pH down to 6.0 ± 0.2. The emulgel base was then mixed homogeneously with CoQ10 powder, CoQ10 solution in oleic acid and Protransf-CoQ10 to produce three distinct kinds of emulgel: CoQ10-Ole, Protransf-CoQ10, and CoQ10, in that order (36).

CoQ10-loaded protransfersome emulgel (Protransf-CoQ10 Emulgel) preparation  (37)

By incorporating A protransfersome emulgel loaded with CoQ10 was produced by incorporating with a final CoQ10 content of 1%, the Protransf-CoQ10 into the emulgel base(37).  In order to create a homogenous emulgel basis Triethylamine Tween 80 and Span 80 (1:1) were combined with (TEA). after Carbopol 940 was added to Reduce the pH to 6.0 +/- 0.2. After adding Protransf-CoQ10, CoQ10 solution in oleic acid, and CoQ10 powder to this emulgel foundation, they were thoroughly mixed to create Protransf-CoQ10 emulgel, CoQ10-Ole emulgel, and CoQ10 emulgel, respectively (38).

Factor to be considered of formulation

1) Therapeutic & Targeting Strategy

  • Clinical objectives : collagen/elastin support, antioxidant/mitochondrial support, and MMP down-regulation; establish quantifiable goals (TEWL ↓, corneometry ↑, wrinkle depth ↓) (39)
  • Target depth: Choose enhancers and processes based on the stratum corneum reservoir the
  • viable epidermis/up.per dermis (40).
  • Dose and use pattern : 1-2 × daily; compatibility with retinoids and sunscreen (41).

2. API (CoQ10) Considerations:

  • Solubility & loading: Because CoQ10 is very lipophilic, it should be soluble in the selected oil/surfactant mixture and have a target load (often 0.1–1% w/w) (42).
  • Stability: • Heat, light, and oxygen sensitivity—this includes amber/airless packs, oxygen-minimized processing, and antioxidants like tocopherol (43).
  • Particle location: To optimize flow, make sure CoQ10 is located in the interfacial region or oil core (44).

3.Vehicle Design (Microemulsion):

  • Oil phase selection: Cottonseed or other skin-friendly oils with high CoQ10 solubility, isopropyl myristate, and medium-chain triglycerides (capric/caprylic) are examples (45).
  • Surfactant system: non-ionic (e.g., Cremophor EL, Polysorbate 80); verify the necessary HLB for the oil phase; and take into account co-surfactants (propylene glycol, Transcutol) to enlarge the microemulsion area (46).
  • Smax & phase behaviour: To map Winsor regions, Maximize Km (surfactant: co-surfactant ratio) by analysing pseudo-ternary phase diagrams that) (47).
  • Droplet size: Aim for transparency and stability at ~20–200 nm; smaller often results in better deposition/flux (48).
  • Zeta potential/stability: ensure thermodynamic stability (no creaming or cracking on dilution); target |ζ| ≥ ~20 mV (or employ steric stabilization via non-Ionics) (49).
  • Water activity & feel: For the comfort of your skin, use humectants (glycerine/PG); weigh breathability against occlusive (50).

4.  Skin Penetration & Regeneration Aids:

  • Penetration enhancers: Use transcutol, IPM, and PG at the lowest effective dosage possible to prevent irritation (51).
  • Barrier-support actives: collaborate with vitamin E (which also shields CoQ10) and pair with hyaluronic acid, panthenol, and ceramides (52).
  • Irritation liability: Avoid using strong solvents; the aqueous phase's pH should be between 5.0 and 6.0 to match the skin's (53).

5.Rheology & Aesthetic Conversion:

  • In-use form: Cream or gel versus thin microemulsion. For a spreadable, non-dripping texture, convert using polymeric emulsifiers or carbomers/xanthan (54).
  • Viscosity target: determined by the type of pack (1,500–8,000 cP for tubes; lower for pumps/sprays, for example) (55).
  • Sensory: Fast absorption, little soaping, non-stickiness, and either hypoallergenic or fragrance-free (56).

6. Process & Scale-Up:

  • Order of addition: Before titrating water, completely dissolve CoQ10 in oil or Smax; controlling the temperature (40–50 °C frequently aids solubilization but prevents oxidation) is important (57).
  • Shear & time: little shear (microemulsions create on their own), but make sure everything is mixed well; if possible, use a nitrogen blanket (58).
  • Robustness: Tolerance for temperature cycling (4/40 °C), pH fluctuations, and high water dilution (rinse-off danger) (59).

7.Critical Quality Attributes (CQAs):

  • CoQ10 assay and content homogeneity.
  •  Globule size/PDI (DLS), appearance/transmittance, pH, viscosity, and ζ-potential (60).
  •  Ex-vivo penetration (Franz cells on pig or human skin) and in-vitro release (dialysis/Franz donor) (61).
  •  Micro (effectiveness of preservation systems in high-solvent matrices).  (62).

8.Efficacy & Safety Testing:

  • Ex-vivo/in-vivo markers: biomarkers (such as procollagen I, elastin, and MMP-1) and biometrics (corneometry, cytometry, and profilometry) (63).
  • Irritation/sensitization: • Patch testing or HRIPT; modify scent and boosters (64).
  • Photostability: According to UVA/UVB exposure studies, "use with sunscreen" is advised for daytime use (65).

9. Preservation & Compliance:

  • Preservatives: Organic acids or parabens (take into account customer preferences and regional restrictions) ± phenoxyethanol (66).
  • pH window: For skin and preservative efficacy, use 5.0–6.0.
  • Regulatory & claims:  Microemulsion claim substantiation, OTC/cosmetic limits, and ISO 16128 (natural index) if necessary (67).

10. Packaging & Shelf-Life:

  • Oxygen/light control: Amber PET, alu-laminate tubes, and airless pumps (68).
  • Leachable/extractables: Check with solvents and co-solvents.
  • Accelerated/real-time stability: Transport vibration, freeze-thaw, and temperatures of 40 °C/75%RH and 25 °C/60%RH (69).

Evaluation parameter:

1). Appearance & Basic Physicochemical:

  • Appearance/clarity/colour/odour (visual; %T at 600–700 nm for clarity) (70).
  • pH (25 °C): 5.0 to 6.0 skin-friendly
  • Conductivity: o/w versus w/o acknowledgment
  • Refractive index
  • Density & spread ability (slip time or grams second)
  • Viscosity & rheology: yield stress, thixotropy index, and flow curve (71)

2). Globule Metrics (Critical Quality Attributes):

  • Droplet size (Z-avg, nm) and PDI (DLS)
  • Zeta potential (mV) or evidence of steric stabilization
  • Interfacial tension (optional)
  • Morphology (TEM/cryogenic-TE M/AFM; optional) (72)

3). Thermodynamic/Physical Stability:

  • Centrifugation (e.g., 5,000–10,000 30 minutes, rpm )
  •  Cycles of heating and cooling, such as 4/40 °C, 6 cycles )
  • Freeze–thaw (−20/25 °C, 3–6 cycles)
  • Accelerated/long-term ICH (such as 25 °C/60%RH and 40 °C/75%RH.) (72)
  • Photostability (ICH Q1B; Assay/Colour)(73)

4).  CoQ10 Assay & Quality:

  • Drug content (HPLC/UPLC), content uniformity
  • Encapsulation/solubilization efficiency (%)
  • Degradation profile: value of peroxide, associated compounds, and colour change (73)
  • Antioxidant co-actives (tocopherol) assay if used

5) In-Vitro Release & Permeation:

  • Release (IVRT: Franz cell/dialysis; Higuchi/Korsmeyer-Peppas model fitting (74)
  • Ex-vivo skin permeation (Franz cells): human/porcine skin
  • A permeability coefficient (Kp) and flux (J, µg·cm?²·h?¹)
  • Lag time (tL))
  • Skin retention and deposition (µg·mg?¹ tissue)—sectioning or stripping tape (75)
  • Enhancer effect vs control vehicle.
  • Enhancer effect vs control vehicle.

6) Skin Regeneration & Bioactivity Markers:µ

  • Antioxidant capacity: Lipid peroxidation inhibition, DPPH/ABTS (76)
  • Cell assays (in-vitro): • Pro-collagen I, elastin, and MMP-1 by ELISA/qPCR; MTT/Alamar Blue viability; ROS reduction; and HaCaT/dermal fibroblasts (77)
  • Mitochondrial function: ATP levels (optional), Δψm (JC-1

7) Safety & Irritation:

  • In-vitro irritation screens: RBC homolysis (for solvents), HET-CAM, and EpiDermTM ET-50 (78)
  • Patch tests/HRIPT) Dermatologist-scored erythema/oedema (occlusive, 24–48 hours) (79)
  • Phototoxicity (According to the region, 3T3 NRU or in vivo)
  • Microbial limits (TAMC/TYMC) & Preservative Efficacy Test (USP <51>/Ph. Eur. 5.1.3) (80)
  • Heavy metals/residual solvents

8) Product Performance on Skin (In-vivo/Clinical/Instrumental): (81)

  • Hydration: Corneometry (Δ vs baseline/placebo)
  • Barrier function: TEWL (g·m?²·h?¹)
  • Elasticity/firmness: Cutometer (R0, R2, R5), blastomere
  • Wrinkle/texture: 3D profilometry/PRIMOS/Vasia; mean wrinkle depth, Ra/Rz (82)
  • Pigment/erythema: Mexameter or colorimetry
  • Subjective sensory panel: After-feel, tack, absorption, and greasiness (Likert scale) (83)

9) Formulation Compatibility & Packaging:

  • Leachable/extractables with pump/tube (GC–MS/LC–MS)
  • Oxygen/light ingress (headspace O?, amber/airless performance) (84)
  • Wipe-off/transfer resistance (for leave-on)
  • pH drift & viscosity drift over shelf-life

10) Regulatory/Documentation (QbD-friendly):

  • Design Space evidence: (Oil %, Smix %, Km) pseudo-ternary phase diagram + DoE (85).
  • CPPs/CQAs linkage: Acceptance standards (e.g., test 95–105%; PDI < 0.30; size < 150 nm) (86).
  • Stability specs: assay, microstructure, viscosity, pH, PDI, droplet size, micro (87).
  • Label claims substantiation (antioxidant/anti-wrinkle/hydration) (88).

Identification Test :

A) Compendial ID (Core):

1) FT-IR match (EP/JP style):

Purpose:  In accordance with the official reference standard (CRS), CoQ10 functional  groups are confirmed (89).

Sample preparation (from microemulsion):

  • Use n-hexane (3×) to extract 1-2 g of the product. Blend organic layers, let them evaporate in N?, and shield them from light. (90)
  • Press to disk (or use ATR) after mixing residue with dry KBr.
    Test: Record 4000–600 cm?¹ spectrum.
    Acceptance: CoQ10 CRS (European Pharmacopoeia ID A) spectrum concordance. Future Drugs (91).

2) HPLC–UV retention time match (EP/USP style):

Purpose:   Chromatographic behaviour for orthogonal identification (92).

Sample preparation :

  • The weighted product should be diluted in isopropanol or acetonitrile:isopropanol (keep out of direct sunlight). Use a gentle sonication and filter (0.45 μm PTFE) (93).
  • Typical system (compendial precedent): UV 275 nm, C18 (L1), ~4.6 × 150 mm, 35 °C. (MeOH/ACN/IPA may be the mobile phase; use your verified system.) (94).
  • Procedure: Inject the test solution and the reference solution (CoQ10 CRS/USP RS) (95).
  • Acceptance: The reference peak RT (EP ID B/USP monograph practice) is matched by the major peak RT in the test. To be sure, add co-injection (spike) (96).

B) Supportive / Rapid Screens (Use alongside A or B):

3) UV–Vis λmax confirmation

Purpose: Look for the oxidized CoQ10 (ubiquinone) chromophore quickly. (97)

Sample preparation:  In ethanol or isopropanol, extract; dilute to approximately 5–15 µg/mL.
Test:Scan200–400nm.
 (98).

Acceptance:

The absorbance ratio is in line with the reference solution, and the λmax is prominent at 275–278 nm with the expected spectral shape. (Only use in complex matrices as a supporting ID; do not use it alone.) (99).

4) TLC Rf match (screen)

Plate: 60 F??? silica gel. Mobile phase (for instance): 9:1 (optimize) n-hexane: ethyl acetate Detection: UV at 254 nm; iodine vapor is optional.
Acceptance: A positive spike test (co-spot overlays) and a single orange-yellow spot for testing with the Rf ≈ reference. (The qualitative ID approach is documented as appropriate; internal validation is conducted.) (100).

C) Enhanced Specificity (when matrix is complex):

5) HPLC with peak-purity (PDA) or LC-EC

  • PDA: The spectra throughout the peak apex and edges match the reference spectrum, and the primary peak's peak-purity index passes (101).
  • Electrochemical detection: Run against. reference; retention time match + response ratio within limits; extremely sensitive for CoQ species (102).

6) Orthogonal LC–MS (if available)

  • Purpose: Ubidecarenones in the extract was confirmed by mass (103).
  • Acceptance: Consistent with the reference standard, molecular ions and fragment ions are used  as internal SOP. Pharmacopeias’ usually use IR/RT for identification, however MS works well for intricate cosmetics.) (104).

D) Practical notes for a Microemulsion Matrix

  • Light/Oxygen: Light causes CoQ10 to darken and deteriorate, therefore process and test under dim light or N? (105).
  • Extraction checks: To make sure your extraction doesn't skew ID, include recovery trials by spiking the blank microemulsion with known CoQ10 (106)
  • System suitability (HPLC): Any formulation excipient peak resolution; duplicate injection %RSD ≤2%; RT %RSD ≤1%. based on your verified approach and compendial standards (107).

Minimal ID Package for Batch Release (suggested)

  1. FT-IR match vs. EP CRS (pass/fail).
  2. HPLC–UV (275 nm) RT match + spike; optional peak-purity.
  3. UV–Vis λmax ~275–278 nm as supportive. Validate the chosen procedure(s) per ICH Q2(R2) (specificity, precision, accuracy, range, robustness) (108).

Current and Future Developments:

  • Microemulsions (MEs) improve healing, penetration, and solubility. In animal wound models, CoQ10-loaded MEs (such as IPM/Cremophor EL/Transcutol HP) promote re-epithelialization, penetrate better than creams, create <20 nm droplets, and are thermodynamically stable.
  • Skin from ME has higher levels of CoQ10 than skin treated with hydrophilic cream, according to validated HPLC tape-stripping.

Clinical signals for anti-ageing are positive but modest

 

  • The evidence base is currently tiny and frequently sponsored by the industry, although short trials (2–12 weeks) demonstrate improvements in elasticity and decreases in wrinkle depth/roughness.
  • Nanostructured lipid carriers and nano emulsions/hydrogels exhibit improved penetration and antioxidant properties; liposomal films are investigated for wound healing.

CONCLUSION

According to our research, the microemulsion was a thermodynamically stable and efficient CoQ10 carrier.  Following topical treatment, the optimized CoQ10-loaded microemulsion showed improved skin accumulation and a better release profile.  Better wound healing efficacy was also demonstrated by the microemulsion in fibroblasts and keratinocytes, two essential cells for skin regeneration. Given their superior solubilizing properties and thermodynamic stability, which can be applied to other pharmaceutical components, such microemulsions may be a desirable carrier for pharmaceutical and cosmetic applications.  They wouldn't cause skin irritation or toxicity when used topically. Because of has enhanced penetrating effectiveness and excellent solubility, microemulsions as drug carriers have the potential to be more advantageous than traditional formulations (such as creams, lotions, and gels) from a scientific standpoint. From an industrial standpoint, this is because of its minimal preparation costs and simplicity of scaling up, which may enable a greater variety of transdermal and topical uses.

ACKNOWLEDGEMENT:

We are deeply appreciative of the Gautam College of Pharmacy's ongoing assistance and collaboration in completing this job.

 

 

REFERENCES

    1. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease.   Nature Reviews Immunology. 2009;9(10):679–91.
    2. Madison KC. Barrier function of the skin:“la raison d'etre” of the epidermis. Journal of investigative dermatology. 2003;121(2):231–41.
    3. Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. Journal of investigative dermatology. 1994;103(5):731–40.
    4. Rawlings AV, Harding CR, Watkinson A, Scott IR. Dry and xerotic skin conditions.  Skin moisturization: CRC Press; 2002. p. 143–68.
    5. Fabin B, Touitou E. Localization of lipophilic molecules penetrating rat skin in vivo by  quantitative autoradiography. International journal of pharmaceutics. 1991;74(1):59–65.
    6. Guy RH, Hadgraft J. Transdermal drug delivery: M. Dekker New York; 2003.
    7. Lindman B, Danielson I. The definition of microemulsion. Colloid Surf. 1981;3(391392.3).
    8. Santos P, Watkinson A, Hadgraft J, Lane M. Application of microemulsions in dermal and transdermal drug delivery. Skin pharmacology and physiology. 2008;21(5):246–59.
    9. Ryu KA, Park PJ, Kim S-B, Bin B-H, Jang D-J, Kim ST. Topical delivery of coenzyme Q10 loaded microemulsion for skin regeneration. Pharmaceutics. 2020;12(4):332. doi:10.3390/pharmaceutics12040332
    10. U.S. Food and Drug Administration (FDA). In Vitro Permeation Test (IVPT) Studies for Topical Drug Products Submitted in ANDAs: Guidance for Industry. 2022 Nov 30.
    11. International Council for Harmonization (ICH). Q2(R2) Validation of Analytical Procedures. 2023 Nov 30.
    12. Ait Touchente Z, Laraba Djebari F, Polidori C, et?al. Exploring the versatility of microemulsions in cutaneous drug delivery. Pharmaceutics. 2023;15(5):1450.
    13. Alnemari RM, Brüßler J, Keck CM. Assessing the oxidative state of the skin by combining classical tape stripping with ORAC assay. Pharmaceuticals (Basel). 2022;15(5):520. doi:10.3390/ph15050520
    14. Shah R, Gandhi J, Shah M, Tiwari P, Chaudhary B, Shah V. Nanoemulsions for topical delivery: formulation, applications and recent advances. J Microencapsul. 2025:1–22. doi:10.1080/02652048.2025.2531778
    15. Knott A, Reuschlein K, Mielke H, et?al. Topical treatment with coenzyme Q10 containing formulas improves skin’s Q10 levels and mitochondrial function. Biofactors. 2015;41(6):388–396.
    16. Ayunin Q, Miatmoko A, Soeratri W, et?al. Improving the anti ageing activity of coenzyme Q10 through protransfersome loaded emulgel. Sci Rep. 2022;12:906. doi:10.1038/s41598-021-04708-4
    17. Virani A, Shah S, Patel M, et?al. A study of microemulsion systems for transdermal delivery. J Pharm Sci. 2023;112(9):2867–2880.
    18. Chatzidaki MD, Papadimitriou V, Xenakis A. Advancements in nanoemulsion based drug delivery over the last five years. Pharmaceutics. 2025;17(5):512.
    19. Chedik L, Diallo A, Ficheux A S, Roudot A C. An update of skin permeability data based on a systematic review. Sci Data. 2024;11:87.
    20. Lane ME, Levis KA, Benson HAE. In vitro permeation testing for evaluation of drug delivery from topical formulations. J Control Release. 2024;361:1–15.
    21. Neupane R, Boddu SHS, Renukuntla J, et?al. Alternatives to biological skin in permeation studies. Pharmaceutics. 2020;12(2):152.
    22. Guy RH, Hadgraft J, Lane ME. Transdermal Drug Delivery. 2nd ed. CRC Press; 2021.
    23. Wilson RJ, et?al. Nanoemulsions for drug delivery. Nano Res. 2022;15(9):7550–7576.
    24. 24.Zhou Y, Zhang X, Li J, et?al. Topical delivery of ceramide by oil in water nanoemulsions: design and evaluation. Biomolecules. 2025;15(5):608.
    25. Dragicevic N, Maibach HI. Coenzyme Q10 loaded nanoemulsion hydrophilic gel: formulation and skin delivery. Colloids Surf B Biointerfaces. 2024;231:113611.
    26. Nair RS, Kallakunta VR, Panchagnula U, et?al. Optimizing in vitro skin permeation studies to obtain clinically relevant performance. AAPS PharmSciTech. 2025;26(4):143.
    27. United States Pharmacopeia. General Chapter <51> Antimicrobial Effectiveness Testing. USP–NF. Rockville, MD; 2024.
    28. International Council for Harmonisation (ICH). Q1B Photostability Testing of New Drug Substances and Products. 2023.
    29. Cirilli I, Damiani E, Dludla PV, et?al. Role of coenzyme Q10 in health and disease: an update on clinical applications. Antioxidants (Basel). 2021;10(9):1297.
    30. Gasmi A, Jawhara S, Menzel A, et?al. Coenzyme Q10 in aging and disease. Antioxidants (Basel). 2024;13(1):87.
    31. Sood B, Patial V, Shukla R. Coenzyme Q10. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024.
    32. Musakhanian J, Arrighi A. Understanding microemulsions and nano emulsions in dermal and transdermal delivery. J Pharm Sci. 2025;114(6):1761–1784.
    33. Assaf SM, El Kersh RA, Taha AA, et?al. Jojoba oil based microemulsion for transdermal drug delivery. Res Pharm Sci. 2021;16(4):391–402.
    34. Wiegand C, Heinemann C, Elsner P, Hipler U C. Keratinocyte and fibroblast wound healing in vitro is differentially influenced by biomaterials. Biomedicines. 2021;9(12):1802.
    35. Konop M, Kloss S. Keratin biomaterials in skin wound healing—an old player with new tricks. Biomedicines. 2021;9(12):1561.
    36. Health Canada. Natural Health Product Monograph: Coenzyme Q10 (Ubiquinone 10). 2025.
    37. Orozco D, Matkovic SR. Determination of ubidecarenone (coenzyme Q10) by HPLC UV: single laboratory validation. J AOAC Int. 2007;90(5):1208–1216.
    38. Moser CL, LaGrange C, Holliday R, et?al. Comparison of compendial antimicrobial effectiveness tests: USP <51>, EP 5.1.3, JP 19. PDA J Pharm Sci Technol. 2011;65(6):519–530.
    39. Knott A, Reuschlein K, Mielke H, Schlattmann P, Gatermann C, Kolbe L. Topical coenzyme Q10 formulas improve skin mitochondrial function. Biofactors. 2015;41(6):388–396. doi:10.1002/biof.1237
    40. Lain ET, Zielinski J, Berson D. Coenzyme Q10 in skin aging and rejuvenation. J Clin Aesthet Dermatol. 2024;17(5):E60–E68.
    41. Virani A, Shah S, Patel M, Rathod D, Koshy M. Microemulsion systems for transdermal delivery. J Pharm Sci. 2023;112(9):2867–2880. doi:10.1016/j.xphs.2023.05.024
    42. Musakhanian J, Arrighi A. Dermal micro/nanoemulsions. J Pharm Sci. 2025;114(6):1761–1784. doi:10.1208/s12249-024-02997-2
    43. Ait Touchente Z, Laraba Djebari F, Polidori C, et?al. Microemulsions for cutaneous delivery. Pharmaceutics. 2023;15(5):1450. doi:10.3390/pharmaceutics15051450
    44. Liu D, Neill OC, Guttman Yassky E. Tape strips in inflammatory skin disease. Br J Dermatol. 2025;192(6):849–860. doi:10.1093/bjd/ljaf275
    45. Rowe DJ, Toomey DP, O’Neill S, McCarron PA. Fresh vs frozen thawed porcine skin for tape stripping. Skin Pharmacol Physiol. 2024;37(5):324–333. doi:10.1159/000538211
    46. FDA. IVPT Guidance for Topical Products (ANDAs). 2022. Available from: https://www.fda.gov/media/162475/download
    47. ICH. Q1B Photostability Testing. 2019 update. Available from: https://www.fda.gov/media https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf
    48. Benson HAE. Penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23–33. doi:10.2174/1567201052772915
    49. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137. doi:10.1016/j.addr.2012.09.032
    50. Karadzovska D, Riviere JE. Animal models for percutaneous penetration. Toxicol In Vitro. 2013;27(4):1379–1388. doi:10.1016/j.tiv.2012.08.004
    51. Trommer H, Neubert RHH. Modulation of skin penetration. Skin Pharmacol Physiol. 2006;19(2):106–121. doi:10.1159/000091978
    52. Moghassemi S, Hadjizadeh A. Nanoemulsions across biological barriers. J Control Release. 2014;185:108–125. doi:10.1016/j.jconrel.2014.04.033
    53. Kalia YN, Guy RH. Modeling transdermal release. Adv Drug Deliv Rev. 2001;48(2–3):159–172. doi:10.1016/S0169-409X(01)00117-0
    54. Mitragotri S, Anissimov YG, Bunge AL, et?al. Skin permeability models. Int J Pharm. 2011;418(1):115–129. doi:10.1016/j.ijpharm.2011.02.015
    55. Lawrence MJ, Rees GD. Microemulsions as drug delivery systems. Adv Drug Deliv Rev. 2012;64:175–193. doi:10.1016/j.addr.2012.09.018
    56. Shah R, Eldridge D, Palombo EA, Harding IH. Nanoemulsions for topical delivery. Drug Deliv Transl Res. 2024;14(1):1–24. doi:10.1007/s13346-023-01419-3
    57. van der Merwe D, Riviere JE. Comparative percutaneous absorption. Toxicol Appl Pharmocol. 2005;208(1):42–52. doi:10.1016/j.taap.2005.01.001
    58. Schäfer Korting M, Mahmoud A, Heisig M. Frantz diffusion cells—protocols. In: Dermal Absorption and Toxicity Assessment. 2007:369–392. doi:10.1007/978-3-540-71454-5_21 .
    59. OECD. TG 428: Skin Absorption—In Vitro Method. 2004 (update 2021). doi:10.1787/9789264071087-en
    60. Nair RS, Kallakunta VR, Panchagnula U, et?al. Clinically relevant in vitro skin permeation. AAPS PharmSciTech. 2025;26(4):143. doi:10.1208/s12249-025-03084-1
    61. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles in dermal products. Int J Pharm. 2009;366(1–2):170–184. doi:10.1016/j.ijpharm.2008.10.003
    62. Zhang Z, Tsai PC, Ramezanli T, Michniak Kohn BB. Polymeric nanoparticles for dermal delivery. J Invest Dermatol. 2015;135(7):S1–S10. doi:10.1038/jid.2015.268
    63. van Smeden J, Bouwstra JA. Stratum corneum lipids. Curr Probl Dermatol. 2016;49:8–26. doi:10.1159/000441540
    64. Gehring W. Nicotinamide in dermatology. J Cosmet Dermatol. 2004;3(2):88–93. doi:10.1111/j.1473-2130.2004.00117.x
    65. Bouwstra JA, Honeywell Nguyen PL, Gooris GS, Ponec M. Skin barrier structure and vesicles. Prog Lipid Res. 2003;42(1):1–36. doi:10.1016/S0163-7827(02)00028-0
    66. Barry BW. Mode of action of penetration enhancers. J Control Release. 1987;6(1):85–97. doi:10.1016/0168-3659(87)90054-7
    67. Miastkowska M, Janik Holna M, Szulc J, et?al. Surfactants/co surfactants in microemulsions for dermal delivery. Pharmaceutics. 2021;13(10):1487. doi:10.3390/pharmaceutics13101487
    68. Complex Generics. Implementing FDA’s IVPT Guidance Recommendations: Step by Step Illustration. 2023. Available from: https://www.complexgenerics.org/education-training/implementing-fdas-ivpt-guidance-recommendations-a-step-by-step-ilustration/
    69. Kumar M, Manivannan S, Shahid M, et?al. Franz diffusion cell and its implication in skin permeation studies. J Dispersion Sci Technol. 2024;45(11):1806–1825. doi:10.1080/01932691.2023.2188923
    70. U.S. FDA. Best Practices for Topical Generic Product Development and ANDA Submission (Webinar). 2022 Aug 11. Available from: https://www.fda.gov/drugs/news-events-human-drugs/best-practices-topical-generic-product-development-and-anda-submission-08112022
    71. OECD. Test No. 428: Skin Absorption: In Vitro Method. 2024 update. Available from: https://www.oecd.org/content/dam/oecd/en/publications/reports/2004/11/test-no-428-skin-absorption-in-vitro-method_g1gh4b52/9789264071087-en.pdf
    72. Friend DR. In vitro skin permeation techniques. J Control Release. 1992;18(3):235–248. doi:10.1016/0168-3659(92)90169-R
    73. 73.Hopf NB, Goebel C, Larese Filon F, et?al. Reflections on the OECD guidelines for in vitro skin absorption. Toxicol Appl Pharmacol. 2020;404:115156. doi:10.1016/j.taap.2020.115156
    74. Žmitek K, Poglajen S, Mervic L, et?al. The effect of dietary intake of coenzyme Q10 on skin parameters and condition. Biofactors. 2017;43(1):132–140. doi:10.1002/biof.1312
    75. Lain ET, Zielinski J, Berson D. The role of coenzyme Q10 in skin aging and rejuvenation: a review. J Clin Aesthet Dermatol. 2024;17(5):E60–E68. Available from https:// mc me ncbi. nlm.nih.gov/articles/PMC11324190/
    76. Manohar G, Jayaprakash P, Rajan R, et?al. Translational potential of nanoemulsion in wound healing. Mater Today Bio. 2025;27:101035. doi:10.1016/j.mtbio.2025.101035
    77. Rna KD, Kiyek?Sadykova D, Makarov R, et?al. Nanoemulsions for wound healing: state of the art. Pharmaceutics. 2023;15(10):2437. doi:10.3390/pharmaceutics15102437
    78. Lane ME. Topical and transdermal delivery systems: current status and future prospects. Pharmaceutics. 2013;5(4):591–594. doi:10.3390/pharmaceutics5040591
    79. Kalia YN, Nonato LB, Lund CH, Guy RH. Development of topical formulations: permeation and penetration measurements. Skin Pharmacol Physiol. 2009;22(5):218–227. doi:10.1159/000231525
    80. OECD. Guidance Notes on Dermal Absorption (No. 156). 2011 (updated 2022). doi:10.1787/9789264125865-en
    81. Ghosh V, Mukherjee A, Chandrasekaran N. Eugenol?loaded antimicrobial nanoemulsion preserves fruit quality. LWT?Food Sci Technol. 2014;56(2):383–389. doi:10.1016/j.lwt.2013.12.002
    82. Badran MM. Formulation and in vitro evaluation of ibuprofen loaded nanoemulsion for topical delivery. Int J Drug Dev Res. 2014;6(2):55–61.
    83. Garti N, Aserin A. Microemulsions for drug delivery. Colloids Surf A. 2001;183–185:41–57. doi:10.1016/S0927-7757(01)00581-1
    84. Shafiq?un?Nabi S, Shakeel F, Talegaonkar S, et?al. Nanoemulsions for transdermal delivery: formulation development and optimization. AAPS PharmSciTech. 2007;8(2):E12. doi:10.1208/pt0802028
    85. Ozogul E, Korkmaz E, Korkusuz F, et?al. Coenzyme Q10?loaded lipid nanoparticles for dermal delivery. J Microencapsul. 2016;33(6):501–510. doi:10.1080/02652048.2016.1220725
    86. Bala I, Bhardwaj V, Hariharan S, Kumar MNVR. Solid lipid nanoparticles: emerging colloidal carriers. Pharmacol Res. 2005;50(2):123–130. doi:10.1016/j.phrs.2004.11.017
    87. Mora?Huertas CE, Fessi H, Elaissari A. Polymer?based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–142. doi:10.1016/j.ijpharm.2009.10.018
    88. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles. Int J Cosmet Sci. 2008;30(3):157–165. doi:10.1111/j.1468-2494.2008.00433.x
    89. Kamel R, Mahmoud A. Cubosomes and hexosomes in topical delivery. Expert Opinm Drug Deliv. 2013;10(10):1335–1349. doi:10.1517/17425247.2013.814427
    90. Hathout RM, Abdelhamid MM, Metwally AA. Ethosomes in topical and transdermal delivery. Curr Drug Deliv. 2010;7(3):187–193. doi:10.2174/156720110791233619
    91. Mura S, Manconi M, Sinico C, et?al. Niosomes for topical delivery: dermal deposition and efficacy. Int J Pharm. 2007;361(1–2):49–55. doi:10.1016/j.ijpharm.2008.05.008
    92. Vollmer DL, West VA, Lephart ED. Enhancing skin health: mechanisms of vitamins and coenzyme Q10. Int J Mol Sci. 2018;19(12):3770. doi:10.3390/ijms19123770
    93. Tan X, Hua H, Wu C, et?al. Design of experiments (DoE) in pharmaceutical development. Saudi Pharm J. 2021;29(12):1176–1187. doi:10.1016/j.jsps.2021.08.015
    94. Montgomery DC. Design and Analysis of Experiments. 10th ed. Wiley; 2020.
    95. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34. doi:10.1038/nbt0109-26
    96. Singh B, Choudhury PK, Ahuja N. Optimization techniques in pharmaceutical   formulations. Drug Discov Today. 2011;16(17–18):887–897. doi:10.1016/j.drudis.2011.07.001
    97. Sawai K, Sakata I, Takeuchi K, et?al. UV–Vis spectrophotometric determination of coenzyme Q10. Anal Sci. 2008;24(2):245–250. doi:10.2116/analsci.24.245
    98. Manasyan L, Spacil Z, Mastovska K. Determination of coenzyme Q10 by UHPLC?UV: method development and validation. LCGC North Am. 2020;38(12):550–559.
    99. Gonzalez?Minero FJ, Bravo?Diaz C. Surfactants in dermal formulations. Cosmetics.   2018;5(3):62. doi:10.3390/cosmetics5030062
    100. Heuschkel S, Goebel A, Neubert RHH. Microemulsions—modern colloidal carrier systems for dermal and transdermal drug delivery. J Pharm Sci. 2008;97(2):603–631. doi:10.1002/jps.21017
    101. Rangel?Vazquez NA, et?al. Zeta potential and stability in colloidal systems. Colloids Interfaces. 2021;5(3):45. doi:10.3390/colloids5030045
    102. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed. Part II. CBS Publishers; 2001.
    103. Council of Europe. European Pharmacopoeia 11.0. Strasbourg: EDQM; 2023.
    104. United States Pharmacopeia–National Formulary (USP 47–NF 42). Rockville, MD: USP; 2024.
    105. ICH. Q1A(R2) Stability Testing of New Drug Substances and Products. 2003 (current). Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
    106. EMA. Guideline on quality of transdermal patches. EMA/CHMP/QWP/608924/2014. 2014. Available from: https://www.ema.europa.eu
    107. OECD. Test Guideline 430: In vitro skin corrosion: TER test. OECD Publishing; 2015.    doi:10.1787/9789264242692-en

Reference

    1. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease.   Nature Reviews Immunology. 2009;9(10):679–91.
    2. Madison KC. Barrier function of the skin:“la raison d'etre” of the epidermis. Journal of investigative dermatology. 2003;121(2):231–41.
    3. Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. Journal of investigative dermatology. 1994;103(5):731–40.
    4. Rawlings AV, Harding CR, Watkinson A, Scott IR. Dry and xerotic skin conditions.  Skin moisturization: CRC Press; 2002. p. 143–68.
    5. Fabin B, Touitou E. Localization of lipophilic molecules penetrating rat skin in vivo by  quantitative autoradiography. International journal of pharmaceutics. 1991;74(1):59–65.
    6. Guy RH, Hadgraft J. Transdermal drug delivery: M. Dekker New York; 2003.
    7. Lindman B, Danielson I. The definition of microemulsion. Colloid Surf. 1981;3(391392.3).
    8. Santos P, Watkinson A, Hadgraft J, Lane M. Application of microemulsions in dermal and transdermal drug delivery. Skin pharmacology and physiology. 2008;21(5):246–59.
    9. Ryu KA, Park PJ, Kim S-B, Bin B-H, Jang D-J, Kim ST. Topical delivery of coenzyme Q10 loaded microemulsion for skin regeneration. Pharmaceutics. 2020;12(4):332. doi:10.3390/pharmaceutics12040332
    10. U.S. Food and Drug Administration (FDA). In Vitro Permeation Test (IVPT) Studies for Topical Drug Products Submitted in ANDAs: Guidance for Industry. 2022 Nov 30.
    11. International Council for Harmonization (ICH). Q2(R2) Validation of Analytical Procedures. 2023 Nov 30.
    12. Ait Touchente Z, Laraba Djebari F, Polidori C, et?al. Exploring the versatility of microemulsions in cutaneous drug delivery. Pharmaceutics. 2023;15(5):1450.
    13. Alnemari RM, Brüßler J, Keck CM. Assessing the oxidative state of the skin by combining classical tape stripping with ORAC assay. Pharmaceuticals (Basel). 2022;15(5):520. doi:10.3390/ph15050520
    14. Shah R, Gandhi J, Shah M, Tiwari P, Chaudhary B, Shah V. Nanoemulsions for topical delivery: formulation, applications and recent advances. J Microencapsul. 2025:1–22. doi:10.1080/02652048.2025.2531778
    15. Knott A, Reuschlein K, Mielke H, et?al. Topical treatment with coenzyme Q10 containing formulas improves skin’s Q10 levels and mitochondrial function. Biofactors. 2015;41(6):388–396.
    16. Ayunin Q, Miatmoko A, Soeratri W, et?al. Improving the anti ageing activity of coenzyme Q10 through protransfersome loaded emulgel. Sci Rep. 2022;12:906. doi:10.1038/s41598-021-04708-4
    17. Virani A, Shah S, Patel M, et?al. A study of microemulsion systems for transdermal delivery. J Pharm Sci. 2023;112(9):2867–2880.
    18. Chatzidaki MD, Papadimitriou V, Xenakis A. Advancements in nanoemulsion based drug delivery over the last five years. Pharmaceutics. 2025;17(5):512.
    19. Chedik L, Diallo A, Ficheux A S, Roudot A C. An update of skin permeability data based on a systematic review. Sci Data. 2024;11:87.
    20. Lane ME, Levis KA, Benson HAE. In vitro permeation testing for evaluation of drug delivery from topical formulations. J Control Release. 2024;361:1–15.
    21. Neupane R, Boddu SHS, Renukuntla J, et?al. Alternatives to biological skin in permeation studies. Pharmaceutics. 2020;12(2):152.
    22. Guy RH, Hadgraft J, Lane ME. Transdermal Drug Delivery. 2nd ed. CRC Press; 2021.
    23. Wilson RJ, et?al. Nanoemulsions for drug delivery. Nano Res. 2022;15(9):7550–7576.
    24. 24.Zhou Y, Zhang X, Li J, et?al. Topical delivery of ceramide by oil in water nanoemulsions: design and evaluation. Biomolecules. 2025;15(5):608.
    25. Dragicevic N, Maibach HI. Coenzyme Q10 loaded nanoemulsion hydrophilic gel: formulation and skin delivery. Colloids Surf B Biointerfaces. 2024;231:113611.
    26. Nair RS, Kallakunta VR, Panchagnula U, et?al. Optimizing in vitro skin permeation studies to obtain clinically relevant performance. AAPS PharmSciTech. 2025;26(4):143.
    27. United States Pharmacopeia. General Chapter <51> Antimicrobial Effectiveness Testing. USP–NF. Rockville, MD; 2024.
    28. International Council for Harmonisation (ICH). Q1B Photostability Testing of New Drug Substances and Products. 2023.
    29. Cirilli I, Damiani E, Dludla PV, et?al. Role of coenzyme Q10 in health and disease: an update on clinical applications. Antioxidants (Basel). 2021;10(9):1297.
    30. Gasmi A, Jawhara S, Menzel A, et?al. Coenzyme Q10 in aging and disease. Antioxidants (Basel). 2024;13(1):87.
    31. Sood B, Patial V, Shukla R. Coenzyme Q10. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024.
    32. Musakhanian J, Arrighi A. Understanding microemulsions and nano emulsions in dermal and transdermal delivery. J Pharm Sci. 2025;114(6):1761–1784.
    33. Assaf SM, El Kersh RA, Taha AA, et?al. Jojoba oil based microemulsion for transdermal drug delivery. Res Pharm Sci. 2021;16(4):391–402.
    34. Wiegand C, Heinemann C, Elsner P, Hipler U C. Keratinocyte and fibroblast wound healing in vitro is differentially influenced by biomaterials. Biomedicines. 2021;9(12):1802.
    35. Konop M, Kloss S. Keratin biomaterials in skin wound healing—an old player with new tricks. Biomedicines. 2021;9(12):1561.
    36. Health Canada. Natural Health Product Monograph: Coenzyme Q10 (Ubiquinone 10). 2025.
    37. Orozco D, Matkovic SR. Determination of ubidecarenone (coenzyme Q10) by HPLC UV: single laboratory validation. J AOAC Int. 2007;90(5):1208–1216.
    38. Moser CL, LaGrange C, Holliday R, et?al. Comparison of compendial antimicrobial effectiveness tests: USP <51>, EP 5.1.3, JP 19. PDA J Pharm Sci Technol. 2011;65(6):519–530.
    39. Knott A, Reuschlein K, Mielke H, Schlattmann P, Gatermann C, Kolbe L. Topical coenzyme Q10 formulas improve skin mitochondrial function. Biofactors. 2015;41(6):388–396. doi:10.1002/biof.1237
    40. Lain ET, Zielinski J, Berson D. Coenzyme Q10 in skin aging and rejuvenation. J Clin Aesthet Dermatol. 2024;17(5):E60–E68.
    41. Virani A, Shah S, Patel M, Rathod D, Koshy M. Microemulsion systems for transdermal delivery. J Pharm Sci. 2023;112(9):2867–2880. doi:10.1016/j.xphs.2023.05.024
    42. Musakhanian J, Arrighi A. Dermal micro/nanoemulsions. J Pharm Sci. 2025;114(6):1761–1784. doi:10.1208/s12249-024-02997-2
    43. Ait Touchente Z, Laraba Djebari F, Polidori C, et?al. Microemulsions for cutaneous delivery. Pharmaceutics. 2023;15(5):1450. doi:10.3390/pharmaceutics15051450
    44. Liu D, Neill OC, Guttman Yassky E. Tape strips in inflammatory skin disease. Br J Dermatol. 2025;192(6):849–860. doi:10.1093/bjd/ljaf275
    45. Rowe DJ, Toomey DP, O’Neill S, McCarron PA. Fresh vs frozen thawed porcine skin for tape stripping. Skin Pharmacol Physiol. 2024;37(5):324–333. doi:10.1159/000538211
    46. FDA. IVPT Guidance for Topical Products (ANDAs). 2022. Available from: https://www.fda.gov/media/162475/download
    47. ICH. Q1B Photostability Testing. 2019 update. Available from: https://www.fda.gov/media https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf
    48. Benson HAE. Penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23–33. doi:10.2174/1567201052772915
    49. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137. doi:10.1016/j.addr.2012.09.032
    50. Karadzovska D, Riviere JE. Animal models for percutaneous penetration. Toxicol In Vitro. 2013;27(4):1379–1388. doi:10.1016/j.tiv.2012.08.004
    51. Trommer H, Neubert RHH. Modulation of skin penetration. Skin Pharmacol Physiol. 2006;19(2):106–121. doi:10.1159/000091978
    52. Moghassemi S, Hadjizadeh A. Nanoemulsions across biological barriers. J Control Release. 2014;185:108–125. doi:10.1016/j.jconrel.2014.04.033
    53. Kalia YN, Guy RH. Modeling transdermal release. Adv Drug Deliv Rev. 2001;48(2–3):159–172. doi:10.1016/S0169-409X(01)00117-0
    54. Mitragotri S, Anissimov YG, Bunge AL, et?al. Skin permeability models. Int J Pharm. 2011;418(1):115–129. doi:10.1016/j.ijpharm.2011.02.015
    55. Lawrence MJ, Rees GD. Microemulsions as drug delivery systems. Adv Drug Deliv Rev. 2012;64:175–193. doi:10.1016/j.addr.2012.09.018
    56. Shah R, Eldridge D, Palombo EA, Harding IH. Nanoemulsions for topical delivery. Drug Deliv Transl Res. 2024;14(1):1–24. doi:10.1007/s13346-023-01419-3
    57. van der Merwe D, Riviere JE. Comparative percutaneous absorption. Toxicol Appl Pharmocol. 2005;208(1):42–52. doi:10.1016/j.taap.2005.01.001
    58. Schäfer Korting M, Mahmoud A, Heisig M. Frantz diffusion cells—protocols. In: Dermal Absorption and Toxicity Assessment. 2007:369–392. doi:10.1007/978-3-540-71454-5_21 .
    59. OECD. TG 428: Skin Absorption—In Vitro Method. 2004 (update 2021). doi:10.1787/9789264071087-en
    60. Nair RS, Kallakunta VR, Panchagnula U, et?al. Clinically relevant in vitro skin permeation. AAPS PharmSciTech. 2025;26(4):143. doi:10.1208/s12249-025-03084-1
    61. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles in dermal products. Int J Pharm. 2009;366(1–2):170–184. doi:10.1016/j.ijpharm.2008.10.003
    62. Zhang Z, Tsai PC, Ramezanli T, Michniak Kohn BB. Polymeric nanoparticles for dermal delivery. J Invest Dermatol. 2015;135(7):S1–S10. doi:10.1038/jid.2015.268
    63. van Smeden J, Bouwstra JA. Stratum corneum lipids. Curr Probl Dermatol. 2016;49:8–26. doi:10.1159/000441540
    64. Gehring W. Nicotinamide in dermatology. J Cosmet Dermatol. 2004;3(2):88–93. doi:10.1111/j.1473-2130.2004.00117.x
    65. Bouwstra JA, Honeywell Nguyen PL, Gooris GS, Ponec M. Skin barrier structure and vesicles. Prog Lipid Res. 2003;42(1):1–36. doi:10.1016/S0163-7827(02)00028-0
    66. Barry BW. Mode of action of penetration enhancers. J Control Release. 1987;6(1):85–97. doi:10.1016/0168-3659(87)90054-7
    67. Miastkowska M, Janik Holna M, Szulc J, et?al. Surfactants/co surfactants in microemulsions for dermal delivery. Pharmaceutics. 2021;13(10):1487. doi:10.3390/pharmaceutics13101487
    68. Complex Generics. Implementing FDA’s IVPT Guidance Recommendations: Step by Step Illustration. 2023. Available from: https://www.complexgenerics.org/education-training/implementing-fdas-ivpt-guidance-recommendations-a-step-by-step-ilustration/
    69. Kumar M, Manivannan S, Shahid M, et?al. Franz diffusion cell and its implication in skin permeation studies. J Dispersion Sci Technol. 2024;45(11):1806–1825. doi:10.1080/01932691.2023.2188923
    70. U.S. FDA. Best Practices for Topical Generic Product Development and ANDA Submission (Webinar). 2022 Aug 11. Available from: https://www.fda.gov/drugs/news-events-human-drugs/best-practices-topical-generic-product-development-and-anda-submission-08112022
    71. OECD. Test No. 428: Skin Absorption: In Vitro Method. 2024 update. Available from: https://www.oecd.org/content/dam/oecd/en/publications/reports/2004/11/test-no-428-skin-absorption-in-vitro-method_g1gh4b52/9789264071087-en.pdf
    72. Friend DR. In vitro skin permeation techniques. J Control Release. 1992;18(3):235–248. doi:10.1016/0168-3659(92)90169-R
    73. 73.Hopf NB, Goebel C, Larese Filon F, et?al. Reflections on the OECD guidelines for in vitro skin absorption. Toxicol Appl Pharmacol. 2020;404:115156. doi:10.1016/j.taap.2020.115156
    74. Žmitek K, Poglajen S, Mervic L, et?al. The effect of dietary intake of coenzyme Q10 on skin parameters and condition. Biofactors. 2017;43(1):132–140. doi:10.1002/biof.1312
    75. Lain ET, Zielinski J, Berson D. The role of coenzyme Q10 in skin aging and rejuvenation: a review. J Clin Aesthet Dermatol. 2024;17(5):E60–E68. Available from https:// mc me ncbi. nlm.nih.gov/articles/PMC11324190/
    76. Manohar G, Jayaprakash P, Rajan R, et?al. Translational potential of nanoemulsion in wound healing. Mater Today Bio. 2025;27:101035. doi:10.1016/j.mtbio.2025.101035
    77. Rna KD, Kiyek?Sadykova D, Makarov R, et?al. Nanoemulsions for wound healing: state of the art. Pharmaceutics. 2023;15(10):2437. doi:10.3390/pharmaceutics15102437
    78. Lane ME. Topical and transdermal delivery systems: current status and future prospects. Pharmaceutics. 2013;5(4):591–594. doi:10.3390/pharmaceutics5040591
    79. Kalia YN, Nonato LB, Lund CH, Guy RH. Development of topical formulations: permeation and penetration measurements. Skin Pharmacol Physiol. 2009;22(5):218–227. doi:10.1159/000231525
    80. OECD. Guidance Notes on Dermal Absorption (No. 156). 2011 (updated 2022). doi:10.1787/9789264125865-en
    81. Ghosh V, Mukherjee A, Chandrasekaran N. Eugenol?loaded antimicrobial nanoemulsion preserves fruit quality. LWT?Food Sci Technol. 2014;56(2):383–389. doi:10.1016/j.lwt.2013.12.002
    82. Badran MM. Formulation and in vitro evaluation of ibuprofen loaded nanoemulsion for topical delivery. Int J Drug Dev Res. 2014;6(2):55–61.
    83. Garti N, Aserin A. Microemulsions for drug delivery. Colloids Surf A. 2001;183–185:41–57. doi:10.1016/S0927-7757(01)00581-1
    84. Shafiq?un?Nabi S, Shakeel F, Talegaonkar S, et?al. Nanoemulsions for transdermal delivery: formulation development and optimization. AAPS PharmSciTech. 2007;8(2):E12. doi:10.1208/pt0802028
    85. Ozogul E, Korkmaz E, Korkusuz F, et?al. Coenzyme Q10?loaded lipid nanoparticles for dermal delivery. J Microencapsul. 2016;33(6):501–510. doi:10.1080/02652048.2016.1220725
    86. Bala I, Bhardwaj V, Hariharan S, Kumar MNVR. Solid lipid nanoparticles: emerging colloidal carriers. Pharmacol Res. 2005;50(2):123–130. doi:10.1016/j.phrs.2004.11.017
    87. Mora?Huertas CE, Fessi H, Elaissari A. Polymer?based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–142. doi:10.1016/j.ijpharm.2009.10.018
    88. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles. Int J Cosmet Sci. 2008;30(3):157–165. doi:10.1111/j.1468-2494.2008.00433.x
    89. Kamel R, Mahmoud A. Cubosomes and hexosomes in topical delivery. Expert Opinm Drug Deliv. 2013;10(10):1335–1349. doi:10.1517/17425247.2013.814427
    90. Hathout RM, Abdelhamid MM, Metwally AA. Ethosomes in topical and transdermal delivery. Curr Drug Deliv. 2010;7(3):187–193. doi:10.2174/156720110791233619
    91. Mura S, Manconi M, Sinico C, et?al. Niosomes for topical delivery: dermal deposition and efficacy. Int J Pharm. 2007;361(1–2):49–55. doi:10.1016/j.ijpharm.2008.05.008
    92. Vollmer DL, West VA, Lephart ED. Enhancing skin health: mechanisms of vitamins and coenzyme Q10. Int J Mol Sci. 2018;19(12):3770. doi:10.3390/ijms19123770
    93. Tan X, Hua H, Wu C, et?al. Design of experiments (DoE) in pharmaceutical development. Saudi Pharm J. 2021;29(12):1176–1187. doi:10.1016/j.jsps.2021.08.015
    94. Montgomery DC. Design and Analysis of Experiments. 10th ed. Wiley; 2020.
    95. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34. doi:10.1038/nbt0109-26
    96. Singh B, Choudhury PK, Ahuja N. Optimization techniques in pharmaceutical   formulations. Drug Discov Today. 2011;16(17–18):887–897. doi:10.1016/j.drudis.2011.07.001
    97. Sawai K, Sakata I, Takeuchi K, et?al. UV–Vis spectrophotometric determination of coenzyme Q10. Anal Sci. 2008;24(2):245–250. doi:10.2116/analsci.24.245
    98. Manasyan L, Spacil Z, Mastovska K. Determination of coenzyme Q10 by UHPLC?UV: method development and validation. LCGC North Am. 2020;38(12):550–559.
    99. Gonzalez?Minero FJ, Bravo?Diaz C. Surfactants in dermal formulations. Cosmetics.   2018;5(3):62. doi:10.3390/cosmetics5030062
    100. Heuschkel S, Goebel A, Neubert RHH. Microemulsions—modern colloidal carrier systems for dermal and transdermal drug delivery. J Pharm Sci. 2008;97(2):603–631. doi:10.1002/jps.21017
    101. Rangel?Vazquez NA, et?al. Zeta potential and stability in colloidal systems. Colloids Interfaces. 2021;5(3):45. doi:10.3390/colloids5030045
    102. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed. Part II. CBS Publishers; 2001.
    103. Council of Europe. European Pharmacopoeia 11.0. Strasbourg: EDQM; 2023.
    104. United States Pharmacopeia–National Formulary (USP 47–NF 42). Rockville, MD: USP; 2024.
    105. ICH. Q1A(R2) Stability Testing of New Drug Substances and Products. 2003 (current). Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
    106. EMA. Guideline on quality of transdermal patches. EMA/CHMP/QWP/608924/2014. 2014. Available from: https://www.ema.europa.eu
    107. OECD. Test Guideline 430: In vitro skin corrosion: TER test. OECD Publishing; 2015.    doi:10.1787/9789264242692-en

Photo
Kumari Varsha
Corresponding author

Associate Professor, Pharmaceutics, Gautam College of Pharmacy ,Hamirpur, Himachal Pradesh,177001

Photo
Tanvi Kapil
Co-author

Research Scholar ,Gautam College of Pharmacy,Hamirpur,Himachal Pradesh,177001

Photo
Mohit Sharma
Co-author

Research Scholar,Pharmaceutical Chemistry,Gautam college of Pharmacy,Hamirpur,Himachal Pradesh,177001

Photo
Dr. Sanjay Kumar
Co-author

Director cum Principal,Gautam College of Pharmacy ,Hamirpur, Himachal Pradesh , 177001

Kumari Varsha, Tanvi Kapil, Mohit Sharma, Dr. Sanjay Kumar, Formulation and evaluation of microemulsion based delivery system for the Co- encapsulation of coenzyme Q10 and hyaluronic acid for skin aging, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 2, 3258-3274. https://doi.org/10.5281/zenodo.18714316

More related articles
The Evolution of Biscuits for Diabetics: From Basi...
Zainab Shaikh , Mantsa Shaikh , Saubiya Shaikh , Zainab Ahmed , A...
A Review on Global Burden of Liver Diseases...
Atif Ahmad Shakeel Ahmad, S.J. Dighade, Wajid Khan Yunus Khan, ...
A Fundamental Understanding of Breast Cancer & Treatment of Breast Cancer...
Adarsha Ganguly, Debapriya Dey , Debarghya Karforma, Hirak Bhowmik , ...
Formulation And Evaluation of Withania Somnifera Syrup for PCOD...
Komal Chavan , Madhavi Kakphale, Shalini Kisan Kawade, Rupal Vijay Kachkure, Maya Sahebrao Jadhav, A...
Gastric Floating Controlled Released Tablet of Diuresis Drug : Formulation and I...
Abhay Dongre, Toshik Lade, Nutan Chahare, Dr. Sachin Dudhe , ...
More related articles
The Evolution of Biscuits for Diabetics: From Basic Snacks to Functional Foods ...
Zainab Shaikh , Mantsa Shaikh , Saubiya Shaikh , Zainab Ahmed , Aasiya Idrisi , Vaishali Chavan, ...
A Review on Global Burden of Liver Diseases...
Atif Ahmad Shakeel Ahmad, S.J. Dighade, Wajid Khan Yunus Khan, ...
The Evolution of Biscuits for Diabetics: From Basic Snacks to Functional Foods ...
Zainab Shaikh , Mantsa Shaikh , Saubiya Shaikh , Zainab Ahmed , Aasiya Idrisi , Vaishali Chavan, ...
A Review on Global Burden of Liver Diseases...
Atif Ahmad Shakeel Ahmad, S.J. Dighade, Wajid Khan Yunus Khan, ...